Minimal Residual Disease Testing - Market Insights, Competitive Landscape, and Market Forecast - 2032

Minimal Residual Disease Testing Market by Test Type (Polymerase Chain Reaction, Flow Cytometry, Next Generation Sequencing, and Others), Application (Leukemia, Lymphoma, Solid Tumors, and Others), End-User (Hospitals, Specialty Clinics, Diagnostic Centers, and Research Centers), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the increasing cases of solid tumors and blood cancers such as leukemia, multiple myeloma, and lymphoma and the increasing product development and launches activities among the key market players.

The minimal residual disease testing market was valued at USD 2.03 billion in 2024, growing at a CAGR of 10.61% during the forecast period from 2025 to 2032 to reach USD 4.51 billion by 2032. The growing demand for minimal residual disease (MRD) testing is primarily fueled by the rising incidence of solid tumors and hematologic malignancies such as leukemia, multiple myeloma, and lymphoma. Advancements in molecular diagnostic technologies have significantly enhanced the accuracy of MRD detection, with the increasing product development and launch activities by key market players continue to strengthen market dynamics. Collectively, these factors are expected to drive robust and sustained growth in the MRD testing market throughout the forecast period from 2025 to 2032.

Minimal Residual Disease Testing Market Dynamics:

According to data from the International Agency for Research on Cancer (2022), in 2022, an estimated 487,294 new cases of leukemia were reported globally, with projections indicating a rise to 746,019 cases by 2045. Despite successful treatment, small amounts of leukemic cells can persist in the body, remaining undetectable by conventional diagnostic methods and increasing the risk of relapse. Minimal Residual Disease (MRD) testing addresses this critical gap by detecting even trace levels of cancer cells with high sensitivity, enabling timely clinical intervention. This is particularly vital in aggressive subtypes such as acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), where MRD status is a key prognostic marker, thereby contributing significantly to the growth of the MRD testing market.

Similarly, IARC (2022) 2022 reported 82,469 new cases of Hodgkin lymphoma and 553,389 cases of non-Hodgkin lymphoma, with these figures expected to rise to 109,308 and 889,841, respectively, by 2045. Many lymphoma patients, particularly those with aggressive types like diffuse large B-cell lymphoma (DLBCL) and certain non-Hodgkin lymphoma subtypes, are at risk of relapse even after initial treatment. MRD testing, utilizing advanced technologies such as next-generation sequencing (NGS) and flow cytometry, plays a vital role in detecting residual cancer cells beyond the capabilities of traditional diagnostics. This allows for more personalized treatment decisions and improved long-term patient outcomes, further driving demand for MRD testing solutions.

According to Cancer Research UK (2022), approximately 6,200 new myeloma cases were diagnosed annually in the UK, while IARC data from 2022 reported over 6,988 cases in Japan. The rising incidence of multiple myeloma is fueling the adoption of MRD testing, as clinicians increasingly depend on it to monitor treatment response, detect early relapse, and guide therapy adjustments. Evolving clinical guidelines now recognize MRD status as a critical prognostic indicator, reinforcing its importance in routine myeloma management.

The overall surge in solid tumors and hematologic malignancies, including leukemia, multiple myeloma, and lymphoma, is significantly propelling the MRD testing market. These cancers often require long-term monitoring and individualized care, making MRD testing an essential tool in modern oncology.

Moreover, ongoing research and development efforts by key market players are further accelerating growth. For instance, in December 2022, Adaptive Biotechnologies announced the launch of clonoSEQ® for assessing MRD in patients with diffuse large B-cell lymphoma using circulating tumor DNA (ctDNA). clonoSEQ enables MRD detection by measuring ctDNA, fragments of DNA shed into the bloodstream by dying cancer cells, to provide a highly sensitive indicator of tumor burden. Such product innovations are expanding the application of MRD testing and strengthening its market trajectory.

However, the limitations associated with sensitivity and specificity and stringent regulatory requirements for product approval, among others, are some of the key constraints that may limit the growth of the minimal residual disease testing market.

Minimal Residual Disease Testing Market Segment Analysis:

Minimal Residual Disease Testing Market by Test Type (Polymerase Chain Reaction, Flow Cytometry, Next Generation Sequencing, and Others), Application (Leukemia, Lymphoma, Solid Tumors, and Others), End-User (Hospitals, Specialty Clinics, Diagnostic Centers, and Research Centers), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the test type segment of the minimal residual disease testing market, the polymerase chain reaction category is estimated to account for the largest market share in 2024. This dominance is primarily driven by the rising global burden of solid tumors and hematologic malignancies, alongside the significant advantages that PCR-based tests offer in detecting these conditions with high precision.

PCR-based MRD testing is a cornerstone of the market due to its exceptional sensitivity and specificity, capable of detecting as few as one cancer cell among 100,000 to 1,000,000 normal cells. This high level of sensitivity enables the identification of minimal disease burden that often goes undetected by conventional methods such as imaging or standard blood tests. By targeting unique DNA or RNA sequences such as immunoglobulin or T-cell receptor gene rearrangements and fusion genes like BCR-ABL in chronic myeloid leukemia, PCR significantly reduces the risk of false positives and ensures detection is limited to disease-specific markers.

One of PCR’s greatest advantages lies in its ability to identify patient-specific molecular signatures, including gene fusions, mutations, and rearrangements, which allows for highly individualized and precise disease monitoring. This facilitates better assessment of treatment efficacy, early prediction of relapse, and informed decision-making regarding treatment intensification or de-escalation. Importantly, PCR enables early detection of recurrence well before clinical symptoms or radiographic changes appear, contributing to improved patient outcomes and survival rates.

As a relatively cost-effective and rapid diagnostic tool, PCR-based MRD assays are increasingly being adopted in routine clinical practice and clinical trials. Their integration into standard care protocols across oncology centers and diagnostic laboratories worldwide is further fueling demand. Technological advancements such as multiplexing and automation have expanded the scope and efficiency of PCR applications in MRD detection, supporting the robust growth of this market segment.

Additionally, rising product development and strategic collaborations are enhancing the capabilities of PCR in MRD testing. For example, in April 2023, Bio-Rad Laboratories, Inc., a global leader in life science and clinical diagnostics, advanced MRD research through multiple collaborations with institutions and biotech companies, leveraging its QX600™ Droplet Digital™ PCR System. These efforts exemplify the ongoing innovation within the PCR segment and underscore its critical role in shaping the future of MRD testing.

Thus, the factors mentioned above are likely to boost the market segment and thereby increase the overall market of minimal residual disease testing across the globe.

North America is expected to dominate the overall minimal residual disease testing market:

North America is projected to hold the largest share of the minimal residual disease testing market in 2024, driven by several key factors. The region's dominance is primarily driven by the rising prevalence of blood cancers and solid tumors, which continues to elevate the demand for advanced diagnostic solutions. Additionally, significant advancements in molecular diagnostic technologies, along with a steady stream of product approvals and launches by leading industry players, are further propelling market growth. These combined drivers firmly position North America as the dominant region in the global MRD testing market.

According to the International Agency for Research on Cancer (2022), an estimated 63,144 new cases of leukemia were reported in the United States in 2022, with projections rising to 88,561 by 2045. Minimal Residual Disease (MRD) testing has emerged as a vital tool in leukemia management, offering ultra-sensitive detection of residual cancer cells that remain after treatment. By enabling early intervention before clinical relapse, MRD testing significantly improves patient outcomes. MRD status is now widely recognized as one of the most powerful prognostic indicators in leukemia, directly influencing treatment decisions, risk stratification, and long-term disease monitoring, thereby driving substantial growth in the MRD testing market across the region.

In Canada, the demand for MRD testing is also on the rise. According to the Canadian Cancer Society (2024), an estimated 4,100 people were diagnosed with multiple myeloma, 6,600 with leukemia, and 11,700 with non-Hodgkin lymphoma. These figures underscore the growing need for advanced monitoring tools like MRD assays to support clinical decision-making and improve survivorship in hematologic malignancies.

Beyond blood cancers, the increasing incidence of solid tumors is also fueling the MRD market expansion. In the United States alone, the estimated number of new breast cancer cases in 2022 was 274,375, with projections reaching 342,421 by 2045, according to IARC data. Similarly, colorectal cancer and other solid tumors continue to contribute significantly to cancer burden. This trend has accelerated the adoption of liquid biopsy-based MRD tests, such as Natera’s Signatera™, which offer a non-invasive, tumor-informed approach for recurrence monitoring and personalized treatment planning. These tests are gaining traction for their ability to detect circulating tumor DNA (ctDNA) and guide real-time clinical decisions in solid tumor management.

Market growth in the U.S. is further strengthened by continuous innovation and strategic advancements from key industry players. For instance, in February 2025, the United States Patent and Trademark Office granted Myriad Genetics a foundational patent for its tumor-informed, high-definition MRD assay. This assay improves ctDNA detection through advanced sequencing techniques, enabling highly sensitive and specific MRD assessment. Similarly, in May 2025, Exact Sciences Corp. announced new data from its Beta-CORRECT clinical validation study, part of the broader GALAXY cohort. The study validated the performance of the company’s Oncodetect™ MRD test in predicting recurrence in stage II-IV colorectal cancer, confirming its role in guiding post-treatment surveillance and therapy decisions.

Therefore, the combination of a rising number of cancer cases coupled with advancements in molecular diagnostic technologies, and technological innovations with ongoing product launches in the domain of MRD testing is expected to significantly propel the growth of the minimal residual disease testing market in North America from 2025 to 2032.

Minimal Residual Disease Testing Market Key Players:

Some of the key market players operating in the minimal residual disease testing market include F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Personalis, Inc., Guardant Health, NeoGenomics Laboratories, Exact Sciences, Foundation Medicine, QIAGEN, Adaptive Biotechnologies, Foresight Diagnostics, ICON plc, Integrated DNA Technologies, Inc., 3B BlacBio Biotech India, Bioartis, EntroGen, Natera, Inc., Labcorp, Bio-Rad Laboratories, Inc., Sysmex Corporation, Veracyte, Inc., Cognixion, Inc., and others.

Recent Developmental Activities in the Minimal Residual Disease Testing Market:

• In June 2025, QIAGEN expanded its minimal residual disease (MRD) testing portfolio through new strategic partnerships with Tracer Biotechnologies and Foresight Diagnostics. These collaborations aim to strengthen QIAGEN’s presence in MRD testing for both solid tumors and blood cancers.
• In April 2025, Labcorp announced the expansion of its precision oncology portfolio with two key solutions. The first, Labcorp Plasma Detect, is designed to help assess the risk of disease recurrence in patients with stage III colon cancer. The second, PGDx elio™ plasma focus Dx, is the first and only FDA-authorized kitted liquid biopsy test for pan-solid tumors, aimed at identifying patients who may benefit from targeted therapies.
• In January 2025, Adaptive Biotechnologies Corporation announced a multi-year exclusive strategic commercial collaboration aimed at advancing MRD monitoring for patients with select blood cancers. The partnership combines Adaptive’s clonoSEQ® MRD test with NeoGenomics’ COMPASS and CHART assessment services, providing clinicians and patients with deeper insights throughout the treatment journey.
• In May 2024, Tempus announced the clinical launch of its minimal residual disease (MRD) test portfolio, which includes the xM test and the xM (NeXT Personal® Dx) test developed by Personalis. These MRD tests are now available to physicians across the U.S. to support early cancer recurrence detection and ongoing residual disease monitoring.

Key takeaways from the minimal residual disease testing market report study

• Market size analysis for the current minimal residual disease testing market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key companies dominating the minimal residual disease testing market.
• Various opportunities available for the other competitors in the minimal residual disease testing market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current minimal residual disease testing market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for minimal residual disease testing market growth in the coming future?

Target audience who can benefit from this minimal residual disease testing market report study

• Minimal residual disease testing product providers
• Research organizations and consulting companies
• Minimal residual disease testing-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in minimal residual disease testing
• Various end-users who want to know more about the minimal residual disease testing market and the latest technological developments in the minimal residual disease testing market.

Frequently Asked Questions for the Minimal Residual Disease Testing Market:

1. What is minimal residual disease testing?

• Minimal residual disease (MRD) testing is a highly sensitive diagnostic method used to detect small numbers of cancer cells that may remain in a patient’s body after treatment, levels that are often undetectable by traditional imaging or lab tests. MRD testing is commonly used in blood cancers such as leukemia, lymphoma, and multiple myeloma, and is increasingly applied to solid tumors through liquid biopsy techniques.

2. What is the market for minimal residual disease testing?

• The minimal residual disease testing market was valued at USD 2.03 billion in 2024, growing at a CAGR of 10.61% during the forecast period from 2025 to 2032 to reach USD 4.51 billion by 2032.

3. What are the drivers for the minimal residual disease testing market?

• The demand for minimal residual disease (MRD) testing is primarily fueled by the rising incidence of solid tumors and hematologic malignancies such as leukemia, multiple myeloma, and lymphoma. Advancements in molecular diagnostic technologies have significantly enhanced the accuracy of MRD detection, with the increasing product development and launch activities by key market players continue to strengthen market dynamics. Collectively, these factors are expected to drive robust and sustained growth in the MRD testing market throughout the forecast period from 2025 to 2032.

4. Who are the key players operating in the minimal residual disease testing market?

• Some of the key market players operating in the minimal residual disease testing market include F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Personalis, Inc., Guardant Health, NeoGenomics Laboratories, Exact Sciences, Foundation Medicine, QIAGEN, Adaptive Biotechnologies, Foresight Diagnostics, ICON plc, Integrated DNA Technologies, Inc., 3B BlacBio Biotech India, Bioartis, EntroGen, Natera, Inc., Labcorp, Bio-Rad Laboratories, Inc., Sysmex Corporation, Veracyte, Inc., Cognixion, Inc., and others.

5. Which region has the highest share in the minimal residual disease testing market?

• North America is projected to hold the largest share of the minimal residual disease testing market in 2024, driven by several key factors. The region's dominance is primarily driven by the rising prevalence of blood cancers and solid tumors, which continues to elevate the demand for advanced diagnostic solutions. Additionally, significant advancements in molecular diagnostic technologies, along with a steady stream of product approvals and launches by leading industry players, are further propelling market growth. These combined drivers firmly position North America as the dominant region in the global MRD testing market.

This product will be delivered within 2 business days.